» Articles » PMID: 18837006

Metabolism of a Sulfur-containing Heteroarotionoid Antitumor Agent, SHetA2, Using Liquid Chromatography/tandem Mass Spectrometry

Overview
Specialty Chemistry
Date 2008 Oct 7
PMID 18837006
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

SHetA2 {[(4-nitrophenyl)amino][2,2,4,4-tetramethylthiochroman-6-yl)amino]methanethione], NSC 726189}, a sulfur-containing heteroarotinoid, selectively inhibits cancer cell growth and induces apoptosis without activation of nuclear retinoic acid receptors (RARs). The objective of this study was to investigate its in vitro metabolism in rat and human liver microsomes and in vivo metabolism in the mouse and rat using liquid chromatography-ultraviolet/multi-stage mass spectrometry (LC-UV/MS(n)) on an ion-trap mass spectrometer coupled with a photo-diode array (PDA) detector. In vitro, in the absence of glutathione (GSH), oxidation of the four aliphatic methyl groups of SHetA2 yielded one mono-, two di-, and one tri-hydroxylated SHetA2 metabolites, which were identified based on their UV and multi-stage mass spectra. In the presence of GSH, in addition to these primary oxidative metabolites, four GSH adducts of SHetA2 and a novel rare form thioether GSH adduct was detected and characterized. In vivo, the monohydroxylated SHetA2 metabolites were also detected in mouse and rat plasma and two GSH adducts were detected in rat liver following intravenous (i.v.) bolus administration of SHetA2 at 40 mg/kg.

Citing Articles

SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention.

Benbrook D Front Cell Dev Biol. 2022; 10:848682.

PMID: 35281109 PMC: 8906462. DOI: 10.3389/fcell.2022.848682.


Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.

Chandra V, Rai R, Benbrook D Cancers (Basel). 2021; 13(10).

PMID: 34066052 PMC: 8150795. DOI: 10.3390/cancers13102322.


Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.

Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook D AAPS J. 2020; 22(2):51.

PMID: 32086622 PMC: 7194160. DOI: 10.1208/s12248-020-0421-z.


Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Ramraj S, Elayapillai S, Pelikan R, Zhao Y, Isingizwe Z, Kennedy A Int J Cancer. 2019; 147(4):1086-1097.

PMID: 31845320 PMC: 7297651. DOI: 10.1002/ijc.32830.


Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study.

Sharma A, Thavathiru E, Benbrook D, Woo S J Pharm Technol Drug Res. 2018; 6.

PMID: 29708233 PMC: 5922436. DOI: 10.7243/2050-120X-6-2.